Viyash Scientific profit and loss

Latest FY26

Revenue: ₹3,420cr+120.5% on FY25
EBITDA: ₹653cr+303.3% on FY25
Net profit: ₹225cr+596.4% on FY25
EPS: ₹4.09+364.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,149	3,420	1,551	1,370	1,421	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	40.4	43.6	14.7	11.0	6.4
	3,189	3,464	1,566	1,381	1,427
	1,296	1,377	617	614	693
	259	251	213	176	122
	−104	−64.8	−18.1	−29.5	18.9
	532	566	281	251	258
	57.3	69.2	60.8	48.1	35.5
	196	234	66.5	61.5	55.7
	572	640	297	298	317
	2,808	3,071	1,517	1,418	1,500
	594	653	162	61.4	12.0
	398	419	95.3	−0.1	−43.7
Profit
	381	393	49.3	−37.3	−72.9
	−43.0	−44.2	−5.0	−17.4	−64.8
	338	349	44.3	−54.6	−138
	43.1	63.2	40.9	13.9	7.5
	81.0	61.2	−28.8	−39.0	−23.2
	124	124	12.1	−25.0	−15.7
	214	225	32.3	−29.6	−122
	214	225	32.3	−29.6	−122
	49.9	107	−21.6	−65.2	−26.1
	264	332	10.7	−94.8	−148
	171	177	21.9	−35.9	−121
	42.6	47.4	10.4	6.3	−0.8
Per share
	₹4.19	₹4.09	₹0.88	−₹1.44	−₹4.88
	₹4.09	₹4.01	₹0.85	−₹1.44	−₹4.88
Other comprehensive income — detail
	49.9	107	−21.6	—	—
	−3.5	−3.1	−0.7	−1.3	−14.4
	−0.9	−0.8	−0.2	—	—
	—	—	—	0.1	0.0
	52.6	109	−21.2	−63.8	−11.7
	205	256	−0.1	−101	−149
	58.5	75.2	10.7	6.5	1.0
Per share — as-filed variants
	₹4.19	₹4.09	₹0.88	−₹1.44	−₹4.88
	₹4.09	₹4.01	₹0.85	−₹1.44	−₹4.88
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,698	1,858	740	610	587
	53.9%	54.3%	47.7%	44.5%	41.3%
Adjusted (ex-exceptional items) — derived
	381	393	49.3	−37.3	−72.9
	−43.0	−44.2	−5.0	−17.4	−64.8
	241	253	35.9	−20.2	−64.6
	₹4.72	₹4.61	₹0.98	−₹0.98	−₹2.58

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIYASH₹227.00

Viyash Scientific Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIDRUGS YATHARTH THYROCARE SUPRIYA STAR SPARC SHILPAMED RUBICONMcap ₹9,916 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,420.9	1,369.7	1,551.4	3,420.3	3,148.7
Other Income	6.4	11.0	14.7	43.6	40.4
Total Income	1,427.3	1,380.7	1,566.1	3,463.9	3,189.1
Expenses
+ Cost of Materials Consumed	693.1	613.7	617.4	1,376.9	1,296.3
+ Purchases of Stock-in-Trade	121.8	175.5	212.6	250.6	259.1
+ Changes in Inventories	18.9	-29.5	-18.1	-64.8	-104.3
+ Employee Benefit Expense	258.4	250.6	281.1	565.5	531.9
+ Finance Costs	35.5	48.1	60.8	69.2	57.3
+ Depreciation & Amortisation	55.7	61.5	66.5	233.6	196.2
+ Other Expenses	316.8	298.0	296.6	639.6	571.8
Total Expenses	1,500.2	1,417.9	1,516.8	3,070.6	2,808.2
EBITDA	12.0	61.4	161.8	652.5	593.9
EBIT	-43.7	-0.1	95.3	418.9	397.8
Profit
PBT before Exceptional Items	-72.9	-37.3	49.3	393.2	380.8
+ Exceptional Items	-64.8	-17.4	-5.0	-44.2	-43.0
Pretax Income	-137.7	-54.6	44.3	349.0	337.9
+ Current Tax	7.5	13.9	40.9	63.2	43.1
+ Deferred Tax	-23.2	-39.0	-28.8	61.2	81.0
Tax Expense	-15.7	-25.0	12.1	124.4	124.1
Net Income	-122.0	-29.6	32.3	224.7	213.8
+ Net Income — Continuing Ops	-122.0	-29.6	32.3	224.7	213.8
+ Other Comprehensive Income	-26.1	-65.2	-21.6	106.9	49.9
Total Comprehensive Income	-148.1	-94.8	10.7	331.6	263.7
Net Income to Common	-121.2	-35.9	21.9	177.3	171.2
Minority Interest	-0.8	6.3	10.4	47.4	42.6
Per Share
Basic EPS	-4.88	-1.44	0.88	4.09	4.19
Diluted EPS	-4.88	-1.44	0.85	4.01	4.09
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-21.6	106.9	49.9
+ Items NOT to be Reclassified to P&L	-14.4	-1.3	-0.7	-3.1	-3.5
+ Tax on Items NOT to be Reclassified	—	—	-0.2	-0.8	-0.9
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.1	—	—	—
+ Items to be Reclassified to P&L	-11.7	-63.8	-21.2	109.2	52.6
Comprehensive Income — Owners of Parent	-149.2	-101.3	-0.1	256.3	205.3
Comprehensive Income — Non-controlling Interests	1.0	6.5	10.7	75.2	58.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	-4.88	-1.44	0.88	4.09	4.19
Diluted EPS — Continuing Operations	-4.88	-1.44	0.85	4.01	4.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	587.1	610.0	739.5	1,857.6	1,697.6
Gross Margin %	41.32	44.53	47.67	54.31	53.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-72.9	-37.3	49.3	393.2	380.8
− Exceptional Items (reconciliation)	-64.8	-17.4	-5.0	-44.2	-43.0
Net Income Adj (tax-effected)	-64.6	-20.2	35.9	253.1	241.0
EPS Adj	-2.58	-0.98	0.98	4.61	4.72
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	49.9	49.9	50.1	87.4	87.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.